Home
Thematic areas
Neuroscience
Pathophysiology and neurological therapeutics of INA (NEURO-INA-IN)

Pathophysiology and neurological therapeutics of INA (NEURO-INA-IN)

+ Info

PRINCIPAL INVESTIGATOR

José Antonio Martínez Orgado
martinezo@salud.madrid.org
Tel. +34 913303000 (Ext. 484753)
ADDRESS

Neonatology Service

San Carlos Clinical Hospital
Prof Martín Lagos, 28040 Madrid

Group information

The group has a strong translational character, implementing a variety of animal models of damage in the immature and developing brain, as well as in other target organs. Its studies are aimed at physiopathological knowledge and the search for therapeutic strategies, with special emphasis on the field of the cannabinoid system. In this sense, the group has become an international reference in this field, which, together with strategic alliances with national and international frontier groups as well as with the pharmaceutical industry, has enabled it to make the leap to clinical trials.

Review

Dr. José Martínez Orgado

Born in Madrid, he earned a Licentiate degree in Medicine from the Complutense University of Madrid (UCM) in 1985 and obtained his PhD in Medicine from the Autonomous University of Madrid in 1999. He is Head of the Neonatology Department at the Hospital Clínico San Carlos-IdISSC and Associate Professor of Paediatrics at the Faculty of Medicine of the UCM, with accreditation as University Professor of since 2012. He leads the Study Group on Cannabinoids in Neonatal Diseases (GECEN), included in the Pathophysiology and Neurological Therapeutics Group of the INA -of which he is the coordinator-, attached to the Neurosciences Area of the IdISSC. Since 1993, he has been conducting studies on the prevention and treatment of acute neonatal neurological pathology, focusing on the neuroprotective role of cannabinoids since 2003, and cannabidiol, in particular, since 2006. Member of the Spanish Society for Cannabinoid Research (SEIC) since 2004, he belonged to its Board of Directors as a member (2012-2015) and Treasurer (2015-2019). He is also a member of the International Cannabinoid Research Society since 2004. Principal Investigator in 8 publicly and 11 privately funded projects. Co-inventor on 2 international patents. Author of 65 international publications, 24 national publications and 15 book chapters, currently reaching an H index (WOS) of 21.

Strategic objectives

To complete pre-clinical studies on efficacy and safety of cannabidiol in models of neonatal hypoxic-ischaemic encephalopathy.
To initiate and lead a multinational clinical trial with cannabidiol and hypothermia in asphyxiated neonates.
To complete pre-clinical studies on efficacy and safety of cannabidiol in models of neonatal cerebral ischaemic artery infarction.
To initiate and lead a clinical trial with cannabidiol in infants and children with refractory epilepsy.
To complete studies on the pathophysiology of multiorgan and extracerebral involvement in brain damage and other pathologies of inflammatory origin (lung, kidney, bladder), and the possible therapeutic role of cannabidiol.
To initiate translational studies on ischaemic bowel damage.

Lines of research

Cannabidiol in the treatment of neonatal hypoxic-ischaemic brain damage.
Cannabidiol for the treatment of refractory epilepsies.
Multi-organ damage of inflammatory origin secondary to cerebral or systemic hypoxic-ischaemic events: pathophysiology and therapeutic role of cannabidiol.